Dec 03 2024
December 3, 2024

ISN Webinar: How GLP1 receptor agonist evolved from weight management drugs to kidney protective therapy?

  • 5 PM CET
This webinar is only available for healthcare professionals

 

This webinar aims to review both experimental studies and clinical trials that examined the efficacy of GLP-1 receptor agonists in mitigating the progression of DKD. Attendees will gain insights into the mechanisms of which GLP-1 receptor agonists exert renoprotective effects. The session will review the clinical practice guidelines, offering practical guidance and discussions on combination therapies, and how to incorporate GLP-1 receptor agonists into current guidelines-directed medical therapies for type 2 diabetic patients with and without CKD. 

Learning objectives:

  • Understand how GLP-1 receptor agonists impact kidney health through mechanisms such as improved glycemic control, reduction of oxidative stress, blood pressure regulation, and modulation of inflammatory pathways.  
  • Review the latest trial evidence of GLP-1 receptor agonists in the management of DKD. 
  • Discuss combination therapies in DKD and provide practice guidance on how to integrate GLP-1 receptor agonists into current treatment protocols in type 2 diabetes and CKD. 

Further reading:

 

This webinar is supported by Novo Nordisk.

Moderators

Sola Bahous (Lebanon)

Speakers

Peter Rossing (Denmark)

Katherine Tuttle (USA)